Tysabri Cohort Study May Need Internal Control Group For Useful Results
A 5,000-patient observational cohort study included in Tysabri's risk management plan for return to market may need an internal control group to provide useful results, members of FDA's Peripheral & Central Nervous System Drugs Advisory Committee indicated March 8
You may also be interested in...
The indication for Biogen Idec/Elan's re-approved multiple sclerosis therapy Tysabri (natalizumab) stops short of limiting it to use as a second-line therapy
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011